Menu
 
Research menu
Jump to menu

Publications:  Prof Adrian Newland Cbe

Doobaree IU, Nandigam R, Bennett D et al.(2016). Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. European Journal of Haematology
10.1111/ejh.12777
Flint SM, Gibson A, Lucas G et al.(2016). A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia. Haematologica vol. 101, (6) 698-706.
10.3324/haematol.2015.137273
http://qmro.qmul.ac.uk/xmlui/handle/123456789/18284
Doobaree IU, Conway K, Nandigam R et al. (2016). CLINICAL CHARACTERISTICS AND TREATMENT PATTERN OF NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA CASES IN THE UNITED KINGDOM IMMUNE THROMBOCYTOPENIA (ADULT) REGISTRY. vol. 101, pp. 139-140.
Doobaree IU, Conway K, Raghava R et al. (2016). Hospital admission data on primary immune thrombocytopenia patients in the National Health Service: Findings using hospital episodes statistics & United Kingdom Immune Thrombocytopenia Registry linked data.
Doobaree IU, Hodges S, Nandigam R et al. (2016). Treatment pattern of immune thrombocytopenia over time: Findings from the United Kingdom Immune Thrombocytopenia (UK ITP) Registry. BRITISH JOURNAL OF HAEMATOLOGY. vol. 173, 71-72.
Provan D, Newland AC(2015). Current Management of Primary Immune Thrombocytopenia. Adv Ther vol. 32, (10) 875-887.
10.1007/s12325-015-0251-z
http://qmro.qmul.ac.uk/xmlui/handle/123456789/10350
Hill QA, Newland AC(2015). Fatigue in immune thrombocytopenia. Br J Haematol vol. 170, (2) 141-149.
10.1111/bjh.13385
http://qmro.qmul.ac.uk/xmlui/handle/123456789/17989
Doobaree U, Nandigam R, Newland A et al. (2015). THE UNITED KINGDOM IMMUNE THROMBOCYTOPENIA (UK ITP) REGISTRY: PRELIMINARY FINDINGS ON BLEEDING EVENTS EXPERIENCED BY ITS PARTICIPANTS. HAEMATOLOGICA. vol. 100, 303-303.
Rizvi H, Butler T, Calaminici M et al.(2015). United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings. BRITISH JOURNAL OF HAEMATOLOGY vol. 169, (4) 590-594.
10.1111/bjh.13330
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7687
Doobaree IUK, Nandigam RC, Newland AC et al. (2015). Demographic characteristics, prevalent comorbidities and treatment patterns: initial analysis from the United Kingdom Immune Thrombocytopenia (UK ITP) Registry. BRITISH JOURNAL OF HAEMATOLOGY. vol. 169, 48-49.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/7625
Bennett D, Doobaree U, Nandigam R et al. (2014). BASELINE CHARACTERISTICS, PLATELET COUNT PROGRESSION AND OCCURRENCE OF COMORBIDITIES AMONG ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UPDATED RESULTS FROM THE UK ITP REGISTRY. HAEMATOLOGICA. vol. 99, 468-468.
Pallavi K, Taylor L, Nandigam R et al. (2014). A single centre experience of treating immune thrombocytopenia with romiplostim - sustained response after treatment discontinuation. BRITISH JOURNAL OF HAEMATOLOGY. vol. 165, 40-40.
Doobaree IU, Nandigam R, Newland A et al. (2014). Thromboembolism in adults with immune thrombocytopenia: a systematic review. BRITISH JOURNAL OF HAEMATOLOGY. vol. 165, 43-43.
Hassan SS, Doobaree U, Nandigam R et al. (2014). Understanding T cell involvement in human immune thrombocytopenia (ITP). BRITISH JOURNAL OF HAEMATOLOGY. vol. 165, 25-25.
Rizvi SMH, Butler T, Calaminici M et al. (2014). United Kingdom Immune Thrombocytopenia (ITP) Registry. Retrospective evaluation of bone marrow fibrosis in adult patients with primary ITP patients: correlation with clinical findings. BRITISH JOURNAL OF HAEMATOLOGY. vol. 165, 10-10.
10.1111/bjh.13330
Hallam S, Provan D, Newland AC(2013). Immune thrombocytopenia -- what are the new treatment options?. Expert Opin Biol Ther vol. 13, (8) 1173-1185.
10.1517/14712598.2013.801451
Kuter DJ, Bussel JB, Newland A et al.(2013). Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. BRITISH JOURNAL OF HAEMATOLOGY vol. 161, (3) 411-423.
10.1111/bjh.12260
Rodeghiero F, Michel M, Gernsheimer T et al.(2013). Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. BLOOD vol. 121, (14) 2596-2606.
10.1182/blood-2012-07-442392
Doobaree IU, Provan AB, Nandigam RC et al.(2013). The United Kingdom immune thrombocytopenic purpura registry. BRITISH JOURNAL OF HAEMATOLOGY vol. 161, 39-40.
Newland A(2012). Thrombopoietin: too much or too little. Hematology vol. 17 Suppl 1, S166-S168.
10.1179/102453312X13336169156816
Farren TW, Giustiniani J, Liu F-T et al.(2011). Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood vol. 118, (8) 2174-2183.
10.1182/blood-2011-02-334326
Cahill MR, Macey M, Newland AC(2011). Aspirin treated subjects show attenuated electron microscopic evidence of platelet activation and a parallel attenuation in thrombin stimulated platelet activation antigens. JOURNAL OF THROMBOSIS AND HAEMOSTASIS vol. 9, 790-791.
Sarpatwari A, Bussel JB, Ahmed M et al.(2011). Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults. Hematology vol. 16, (4) 243-248.
10.1179/102453311X13025568941808
Stasi R, Newland AC(2011). ITP: a historical perspective. Br J Haematol vol. 153, (4) 437-450.
10.1111/j.1365-2141.2010.08562.x
Provan D, Newland AC, Consensus Grp(2011). Guidelines for Immune Thrombocytopenia. NEW ENGL J MED vol. 364, (6) 580-581.
10.1056/NEJMc1013806
Newland A(2011). What's new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists. Med Princ Pract vol. 20, (4) 301-302.
10.1159/000324876
Sarpatwari A, Provan D, Erqou S et al.(2010). Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. Br J Haematol vol. 151, (5) 477-487.
10.1111/j.1365-2141.2010.08377.x
Stasi R, Newland A, Thornton P et al.(2010). Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. ANN HEMATOL vol. 89, (12) 1185-1195.
10.1007/s00277-010-1066-2
Sarpatwari A, Watson S, Erqou S et al.(2010). Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP). Br J Haematol vol. 151, (2) 189-191.
10.1111/j.1365-2141.2010.08322.x
Molineux G, Newland A(2010). Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. BRIT J HAEMATOL vol. 150, (1) 9-20.
10.1111/j.1365-2141.2010.08140.x
Sarpatwari A, Bennett D, Logie JW et al.(2010). Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. HAEMATOL-HEMATOL J vol. 95, (7) 1167-1175.
10.3324/haematol.2009.018390
Kuter J, Newland A, Bussel J et al. (2010). EVALUATION OF EFFICACY AND SAFETY OF LONG-TERM ROMIPLOSTIM TREATMENT FOR PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) ENROLLED IN AN OPEN-LABEL EXTENSION STUDY: A PATIENT COHORT-ANALYSIS. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 95, 76-76.
Provan D, Stasi R, Newland AC et al.(2010). International consensus report on the investigation and management of primary immune thrombocytopenia. Blood vol. 115, (2) 168-186.
10.1182/blood-2009-06-225565
Sarpatwari A, Provan D, Sobnack R et al. (2009). Autologous In-111-Labeled Platelet Sequestration Studies in Patients with Primary Immune Thrombocytopenia (ITP): A Report From the United Kingdom Registry. BLOOD. vol. 114, 950-950.
Bussel JB, Kuter DJ, Newland A et al. (2009). Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study. BLOOD. vol. 114, 285-285.
Newland A(2009). Thrombopoietin receptor agonists in the treatment of thrombocytopenia. Curr Opin Hematol vol. 16, (5) 357-364.
10.1097/MOH.0b013e32832e06e4
Murphy MF, Allard S, Newland AC(2009). Modernizing hospital transfusion laboratory services. TRANSFUSION MED vol. 19, (4) 153-155.
10.1111/j.1365-3148.2009.00937.x
Pullarkat VA, Gernsheirner TB, Wasser JS et al.(2009). Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). AM J HEMATOL vol. 84, (8) 538-540.
10.1002/ajh.21463
Newland A(2009). Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. EUR J HAEMATOL vol. 82, 20-25.
10.1111/j.1600-0609.2008.01209.x
Stasi R, Sarpatwari A, Segal JB et al.(2009). Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. BLOOD vol. 113, (6) 1231-1240.
10.1182/blood-2008-07-167155
Sarpatwari A, Watson S, Anderson H et al. (2008). Health-Related Lifestyle among Adult & Pediatric Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom. BLOOD. vol. 112, 1178-1178.
Kuter DJ, Bussel JB, Newland A et al. (2008). Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label. BLOOD. vol. 112, 154-154.
Sarpatwari A, Bennett D, Logie JW et al. (2008). Thromboembolic Events among Adult Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom General Practice Research Database. BLOOD. vol. 112, 1167-1167.
Liu F-T, Agrawal SG, Movasaghi Z et al.(2008). Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood vol. 112, (9) 3835-3846.
10.1182/blood-2008-04-150227
http://qmro.qmul.ac.uk/xmlui/handle/123456789/1075
Provan D, Newland AC, Amadori S et al.(2008). Rituximab in the treatment of autoimmune haematological disorders. BRIT J HAEMATOL vol. 143, (2) 294-294.
10.1111/j.1365-2141.2008.07326.x
Yu M, Liu F-T, Newland AC et al.(2008). The alpha-5 helix of Bax is sensitive to ubiquitin-dependent degradation. Biochem Biophys Res Commun vol. 371, (1) 10-15.
10.1016/j.bbrc.2008.03.122
Newland A, Bussel J, Stone N et al. (2008). ELTROMBOPAG EFFECTIVELY ELEVATES PLATELETS IN PATIENTS WITH CHRONIC IDIOPATHIC THROMSOCYTOPENIC PURPURA (ITP) REGARDLESS OF SPLENECTOMY STATUS. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 93, 121-121.
Liu F-T, Agrawal SG, Gribben JG et al.(2008). Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood vol. 111, (5) 2797-2805.
10.1182/blood-2007-08-110445
http://qmro.qmul.ac.uk/xmlui/handle/123456789/1076
Agrawal SG, Liu F-T, Wiseman C et al.(2008). Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood vol. 111, (5) 2790-2796.
10.1182/blood-2007-10-110460
http://qmro.qmul.ac.uk/xmlui/handle/123456789/1077
Kuter DJ, Bussel JB, Lyons RM et al.(2008). Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. LANCET vol. 371, (9610) 395-403.
10.1016/S0140-6736(08)60203-2
Newland A (2008). Emerging strategies to treat chronic immune thrombocytopenic purpura. Eur J Haematol Suppl. 27-33.
10.1111/j.1600-0609.2007.01001.x
Provan D, Butler T, Evangelista ML et al.(2007). Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. HAEMATOL-HEMATOL J vol. 92, (12) 1695-1698.
10.3324/haematol.11709
Agrawal SG, Liu FT, Wiseman C et al. (2007). Bax degradation activity is a novel poor prognosis marker of chronic lymphocytic leukemia. BLOOD. vol. 110, 908A-908A.
Bussel JB, Kuter DJ, de Wolf JTM et al. (2007). Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update. BLOOD. vol. 110, 174A-175A.
Pullarkat V, Gernsheimer TB, de Wolf JTM et al. (2007). Reduction in immunoglobulin (IVIG or anti D) use in patients with chronic immune thrombocytopenic purpura (ITP) receiving AMG 531: Results from two phase 3 randomized placebo-controlled trials. BLOOD. vol. 110, 392A-393A.
Tsitsikas DA, Giustiniani J, Skipper A et al. (2007). Universal CD160 expression and the CD5+23+/CD5+19+ ratio in chronic lymphocytic leukemia simpify identification of atypical cases from CD23+ mantle cell lymphoma. BLOOD. vol. 110, 243B-243B.
Farren T, Giustiniani J, Johansson U et al. (2007). Using CD160 as a novel approach to the assessment of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL). BLOOD. vol. 110, 606A-606A.
Jahnke U, Higginbottom K, Newland AC et al.(2007). Cell death in leukemia: passenger protein regulation by topoisomerase inhibitors. Biochem Biophys Res Commun vol. 361, (4) 928-933.
10.1016/j.bbrc.2007.07.117
Higginbottom K, Jahnke U, Newland AC et al.(2007). New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis. Apoptosis vol. 12, (10) 1847-1855.
10.1007/s10495-007-0104-6
Newland A(2007). Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. SEMIN HEMATOL vol. 44, (4) S35-S45.
10.1053/j.seminhematol.2007.11.005
Provan D, Newland AC(2007). Romiplostim. DRUG FUTURE vol. 32, (9) 781-787.
10.1358/dof.2007.032.09.1135519
Aledort LM, Salama A, Kovaleva L et al.(2007). Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac((R))) in chronic immune thrombocytopenic purpura. HEMATOLOGY vol. 12, (4) 289-295.
10.1080/10245330701383908
Auer RL, Dighiero G, Goldin LR et al.(2007). Trinucleotide repeat dynamic mutation identifying susceptibility in familial and sporadic chronic lymphocytic leukaemia. Br J Haematol vol. 136, (1) 73-79.
10.1111/j.1365-2141.2006.06388.x
Newland A, Caulier MT, Kappers-Klunne M et al.(2006). An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol vol. 135, (4) 547-553.
10.1111/j.1365-2141.2006.06339.x
NEWLAND AC, Provan D, Amadori S et al.(2006). Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). vol. 45, 1432-1436.
10.1093/rheumatology/kel098
Stasi R, Amadori S, Osborn J et al.(2006). Borderline thrombocytopenia or mild idiopathic thrombocytopenic purpura? Reply. PLOS MED vol. 3, (8) Article e365, 1435-1435.
10.1371/journal.pmed.0030365
Mcelwaine SM, Johansson U, Kenny D et al. (2006). Global gene expression profiling in patients diagnosed with idiopathic thrombocytopenia (ITP) using affymetrix gene expression arrays. BRITISH JOURNAL OF HAEMATOLOGY. vol. 133, 32-33.
Stasi R, Amadori S, Osborn J et al.(2006). Long-term outcome of otherwise healthy individuals with incidentally discovered borderline, thrombocytopenia. PLOS MED vol. 3, (3) Article e24, 388-394.
10.1371/journal.pmed.0030024
http://qmro.qmul.ac.uk/xmlui/handle/123456789/8202
NEWLAND AC, Provan D, Moss AJ et al.(2006). Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. vol. 81, 19-25.
10.1002/ajh.20515
Johansson U, Lawson C, Dabare M et al.(2005). Human peripheral blood monocytes express protease receptor-2 and respond to receptor activation by production of IL-6, IL-8, and IL-1{beta}. J Leukoc Biol vol. 78, (4) 967-975.
10.1189/jlb.0704422
Newland A, Provan D, Myint S(2005). Preventing severe infection after splenectomy - Risk of malaria and meningitis increases with asplenia - Reply. BRIT MED J vol. 331, (7516) 576-576.
10.1136/bmj.331.7516.576-c
Newland A, Provan D, Myint S(2005). Preventing severe infection after splenectomy - Patients should know the risks, be immunised, and take prophylactic antibiotics. BRIT MED J vol. 331, (7514) 417-418.
10.1136/bmj.331.7514.417
Stasi R, Amadori S, Littlewood TJ et al.(2005). Management of cancer-related anemia with erythropoietic agents: Doubts, certainties, and concerns. ONCOLOGIST vol. 10, (7) 539-554.
10.1634/theoncologist.10-7-539
Cotter F, Su B, Corbo M et al. (2005). GCS-100 a novelgalectin-3 antagonist and caspase9 activating therapy for indolent B-cell malignancies. ANNALS OF ONCOLOGY. vol. 16, 70-70.
Auer R, Costagli A, Newland A et al. (2005). Zebrafish in vivo modelling of the 11Q23 region of deletion in chronic lymphatic leukaemia. ANNALS OF ONCOLOGY. vol. 16, 87-87.
Auer RL, Starczynski J, McElwaine S et al.(2005). Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia. Genes Chromosomes Cancer vol. 43, (1) 1-10.
10.1002/gcc.20159
Johansson U, Macey MG, Kenny D et al.(2005). The role of natural killer T (NKT) cells in immune thrombocytopenia: is strong in vitro NKT cell activity related to the development of remission?. BRIT J HAEMATOL vol. 129, (4) 564-565.
10.1111/j.1365-2141.2005.05495.x
Newland AC, Provan AB, Caulier MT et al. (2005). An open-label, unit dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (Pts) with immune thrombocytopenic purpura (ITP). BRITISH JOURNAL OF HAEMATOLOGY. vol. 129, 43-43.
Auer RL, Costagli A, Newland AC et al. (2005). Definition and zebrafish modelling of the 11 q23 critical region of deletion in CLL. BRITISH JOURNAL OF HAEMATOLOGY. vol. 129, 25-26.
Auer RL, Su B, Corbo M et al. (2005). GCS-100, a Galectin 3 antagonist, is a novel caspase-9 apoptosis activating agent for the treatment of indolent B-cell malignancies. BRITISH JOURNAL OF HAEMATOLOGY. vol. 129, 5-5.
Stasi R, Amadori S, Newland AC et al.(2005). Infliximab chimeric antitumor necrosis factor-alpha monoclonal antibody as potential treatment for myelodysplastic syndromes. LEUKEMIA LYMPHOMA vol. 46, (4) 509-516.
10.1080/10428190400027829
Johansson U, Kenny D, Provan D et al. (2005). Selective reduction of plasmacytoid DCs in peripheral blood from ITP patients. BRITISH JOURNAL OF HAEMATOLOGY. vol. 129, 9-9.
NEWLAND AC, Provan D, Stipa E et al.(2005). Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med. vol. 118, 414-419.
Aledort LM, Salama A, Kovaleva L et al. (2004). An open label, multi center study on the efficacy and safety of a liquid, ready-to-use intravenously administered anti-D immunoglobulin in patients with chronic immune thrombocytopenic purpura. BLOOD. vol. 104, 72B-72B.
Cotter FE, Su B, Corbo M et al. (2004). GCS-100, a Galectin 3 antagonist, is a novel caspase-9 apoptosis activating agent for the treatment of indolent B-cell malignancies. BLOOD. vol. 104, 898A-898A.
Hao J-H, Yu M, Liu F-T et al.(2004). Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res vol. 64, (10) 3607-3616.
10.1158/0008-5472.CAN-03-3648
Johansson U, Macey MG, Kenny D et al.(2004). Alpha-galactosylceramide-driven expansion of human natural killer T cells is inhibited by prednisolone treatment. Br J Haematol vol. 125, (3) 400-404.
10.1111/j.1365-2141.2004.04896.x
Liu F-T, Goff LK, Hao J-H et al.(2004). Increase in the ratio of mitochondrial Bax/Bcl-XL induces Bax activation in human leukemic K562 cell line. Apoptosis vol. 9, (3) 377-384.
10.1023/B:APPT.0000025815.78761.5c
NEWLAND AC, Provan D, Amadori R et al.(2004). Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges. Blood vol. 104,
Provan D, Newland A (2003). Idiopathic thrombocytopenic purpura in adults. J Pediatr Hematol Oncol. vol. 25 Suppl 1, S34-S38.
10.1097/00043426-200312001-00008
Feng WY, Liu FT, Patwari Y et al.(2003). BH3-domain mimetic compound BH3I-2 ' induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria. BRIT J HAEMATOL vol. 121, (2) 332-340.
10.1046/j.1365-2141.2003.04268.x
Jia L, Patwari Y, Kelsey SM et al.(2003). Role of Smac in human leukaemic cell apoptosis and proliferation. ONCOGENE vol. 22, (11) 1589-1599.
10.1038/sj.onc.1206322
Hough RE, Lorigan PC, Poynton C et al.(2003). A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy. INT J ONCOL vol. 22, (2) 421-424.
Provan D, Newland A, Norfolk D et al.(2003). Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. BRIT J HAEMATOL vol. 120, (4) 574-596.
10.1046/j.1365-2141.2003.04131.x
Fu WN, Bertoni F, Kelsey SM et al.(2003). Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. ONCOGENE vol. 22, (3) 451-455.
10.1038/sj.onc.1206147
NEWLAND AC, Provan D, MeaD AJ(2003). Adult idiopathic thrombocytopenic purpura. Hematology vol. 8, 345-357.
10.1080/1024533032000158850
JIA L, Newland AC, Liu FT(2003). Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia. Biochem. Biophys. Res. Commun vol. 310, (3) 856-962.
10.1016/j.bbrc.2003.09.109
Macey M, McCarthy D, Azam U et al.(2003). Ethylenediaminetetraacetic acid plus. citrate-theophylfine-adenosine-dipyridamole (EDTA-CTAD): A novel anticoagulant for the flow cytometric assessment of platelet and neutrophil activation ex vivo in whole blood. CYTOM PART B-CLIN CY vol. 51B, (1) 30-40.
10.1002/cyto.b.10001
NEWLAND AC, Provan D, Williams MA et al.(2003). In vitro cytotoxic effects of stabilizing sugars within human intravenous immunoglobulin preparations against the human macrophage THP-1 cell-line. Hematology vol. 8, 285-294.
JIA L, Newland AC, Liu FT et al.(2003). Potential mechanisms of leukemia cell resistance to TRAIL-induced apoptosis. Apoptosis vol. 8, 601-607.
10.1023/A:1026131425204
Provan D, Newland A(2002). Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults. Br J Haematol vol. 118, (4) 933-944.
10.1046/j.1365-2141.2002.03669.x
Newland A (2002). Progress in the treatment of acute myeloid leukaemia in adults. Int J Hematol. vol. 76 Suppl 1, 253-258.
10.1007/BF03165254
ALLEN PD, Newland AC, Higginbottom K et al.(2002). Etoposide-Mediated Deregulation of the G2M Checkpoint in Myeloid Leukaemic Cell Lines Results in Loss of Cell Survival. Br J. Haemat vol. 119, 956-964.
10.1046/j.1365-2141.2002.03977.x
Macey M, Azam U, McCarthy D et al.(2002). Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 Hematology System. CLIN CHEM vol. 48, (6) 891-899.
Liu F-T, Kelsey SM, Newland AC et al.(2002). Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukaemic cells. Br J Haematol vol. 117, (2) 333-342.
10.1046/j.1365-2141.2002.03418.x
Cummings M, Siitonen T, Higginbottom K et al.(2002). p53-mediated downregulation of Chk1 abrogates the DNA damage-induced G2M checkpoint in K562 cells, resulting in increased apoptosis. BRIT J HAEMATOL vol. 116, (2) 421-428.
10.0000/000368496328155
Newland AC(2002). Treatment of adults with autoimmune thrombocytopenic purpura. Lancet vol. 359, (9300) 4-5.
10.1016/S0140-6736(02)07269-0
Liu FT, Kelsey SM, Newland AC et al.(2001). Generation of reactive oxygen species is not involved in idarubicin-induced apoptosis in human leukaemic cells. Br J Haematol vol. 115, (4) 817-825.
10.1046/j.1365-2141.2001.03216.x
Partheniou F, Kelsey SM, Srinivasula SM et al.(2001). c-IAP1 blocks TNFalpha-mediated cytotoxicity upstream of caspase-dependent and -independent mitochondrial events in human leukemic cells. Biochem Biophys Res Commun vol. 287, (1) 181-189.
10.1006/bbrc.2001.5582
Stanworth SJ, Newland AC(2001). Stem cells: progress in research and edging towards the clinical setting. CLIN MED vol. 1, (5) 378-382.
10.7861/clinmedicine.1-5-378
Jia L, Patwari Y, Srinivasula SM et al.(2001). Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene vol. 20, (35) 4817-4826.
10.1038/sj.onc.1204628
Jia L, Srinivasula SM, Liu FT et al.(2001). Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. BLOOD vol. 98, (2) 414-421.
10.1182/blood.V98.2.414
McBride NC, Cavenagh JD, Ward MC et al.(2001). Liposomal daunorubicin (daunoxome) in combination with cyclophosphamide, vincristine and prednisolone (COPA) as salvage therapy in poor-prognosis non-Hodgkins lymphoma. LEUKEMIA LYMPHOMA vol. 42, (1-2) 89-98.
10.3109/10428190109097680
Jia L, Patwari Y, Kelsey SM et al.(2001). Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of bax. Biochem Biophys Res Commun vol. 283, (5) 1037-1045.
10.1006/bbrc.2001.4895
Yin Y, Allen PD, Jia L et al.(2001). 8-Cl-adenosine mediated cytotoxicity and sensitization of T-lymphoblastic leukemia cells to TNFalpha-induced apoptosis is via inactivation of NF-kappaB. Leuk Res vol. 25, (5) 423-431.
10.1016/S0145-2126(00)00147-8
Fu WN, Kelsey SM, Newland AC et al.(2001). Apaf-1XL is an inactive isoform compared with Apaf-1L. Biochem Biophys Res Commun vol. 282, (1) 268-272.
10.1006/bbrc.2001.4575
Newland AC, Burton I, Cavenagh JD et al.(2001). Vigam-S, a solvent/detergent-treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura. TRANSFUSION MED vol. 11, (1) 37-44.
10.1046/j.1365-3148.2001.00281.x
Gilston V, Williams MA, Newland AC et al.(2001). Hydrogen peroxide and tumour necrosis factor-alpha induce NF-kappa B-DNA binding in primary human T lymphocytes in addition to T cell lines. FREE RADICAL RES vol. 35, (6) 681-691.
10.1080/10715760100301201
Newland AC, Mantsch HH, JIA L et al.(2001). Quantitative determination of apoptosis on leukaemic cells by infrared spectroscopy. Apoptosis vol. 6, 267-276.
10.1023/A:1011383408381
Wu YL, Jiang XR, Lillington DM et al.(2000). Upregulation of lipocortin 1 inhibits tumour necrosis factor-induced apoptosis in human leukaemic cells: a possible mechanism of resistance to immune surveillance. BRIT J HAEMATOL vol. 111, (3) 807-816.
10.1046/j.1365-2141.2000.02397.x
Chapman ES, Azam U, Webb L et al.(2000). The use of the anticoagulant CTAD for the assessment of ex vivo platelet activation on the ADVIA 120 Haematology System. BLOOD vol. 96, (11) 52B-52B.
Shamash J, O'Doherty CA, Oliver RTD et al.(2000). Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?. ACTA ONCOL vol. 39, (7) 857-863.
10.1080/028418600750063622
Return to top